• 7024 malaria professionals are enjoying the free benefits of MalariaWorld today
Home › piperaquine

piperaquine

Open Access | Pharmacokinetics and Disposition: Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria

Submitted by patrick sampao on January 14, 2011 - 12:37
Tags:
Author(s): 
Elizabeth A. Ashley., Kasia Stepniewska.,François Nosten., et al.
Reference: 
European Journal of Clinical Pharmacology, Volume 66, Number 7, 705-712
Access: 
Click here to go to the full article
Contact email: 
smru@tropmedres.ac

The aim of this study was to describe the relationship between piperaquine concentrations measured in capillary blood, venous blood and venous plasma.

_____________________________________________________________

In Vitro Activity of Pyronaridine against Multidrug-Resistant Plasmodium falciparum and Plasmodium vivax

Submitted by Kabogo on November 19, 2010 - 11:38
Tags:
Author(s): 
R. N. Price, J. Marfurt, F. Chalfein, E. Kenangalem, K. A. Piera, E. Tjitra, N. M. Anstey, and B. Russell
Reference: 
Antimicrobial Agents and Chemotherapy, December 2010, p. 5146-5150, Vol. 54, No. 12
Access: 
Click here to go to the Journal
Contact email: 
rprice@menzies.edu.au

Pyronaridine, a Mannich base antimalarial, has demonstrated high in vivo and in vitro efficacy against chloroquine-resistant Plasmodium falciparum.

_____________________________________________________________

Absence of Association between Piperaquine In Vitro Responses and Polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe Genes in Plasmodium falciparum

Submitted by Kabogo on August 18, 2010 - 12:43
Tags:
Author(s): 
Sébastien Briolant, Maud Henry, Claude Oeuvray, Rémy Amalvict, Eric Baret, Eric Didillon, Christophe Rogier, and Bruno Pradines
Reference: 
Antimicrobial Agents and Chemotherapy, September 2010, p. 3537-3544, Vol. 54, No. 9
Access: 
Click here to go to the full article
Contact email: 
bruno.pradines@free.fr

We have analyzed the profiles of 23 of Plasmodium falciparum strains for their in vitro chemosusceptibilities to piperaquine (PPQ), dihydroartemisinin (DHA), chloroquine, monodesethylamodiaquine, quinine, mefloquine, lumefantrine, atovaquone, pyrimethamine, and doxycycline (DOX) in association with polymorphisms in genes involved in quinoline resistance (Plasmodium falciparum crt [pfcrt], pfmdr1, pfmrp, and pfnhe).

_____________________________________________________________

Investigation of reproductive toxicity of piperaquine in mice

Submitted by Kabogo on March 26, 2010 - 16:48
Tags:
Author(s): 
Kevin T. Batty, Brioni R. Moore, Verity Stirling, Kenneth F. Ilett, Madhu Page-Sharp, Keith B. Shilkin, Ivo Mueller, Stephen J. Rogerson, Harin A. Karunajeewa, Timothy M.E. Davis
Reference: 
Reproductive Toxicology, Volume 29, Issue 2, April 2010, Pages 206-213
Access: 
Click here to go to the Journal
Contact email: 
Kevin.Batty@curtin.edu.au

Although we found no significant PQ toxicity, clinical data are lacking and monitoring of women and their infants for biochemical and haematological adverse effects is recommended when PQ is used in pregnancy.

_____________________________________________________________

In Vitro Activities of Piperaquine, Lumefantrine, and Dihydroartemisinin in Kenyan Plasmodium falciparum Isolates and Polymorphisms in pfcrt and pfmdr1

Submitted by Inga on December 7, 2009 - 12:03
Tags:
Author(s): 
Leah Mwai, Steven M. Kiara, Abdi Abdirahman, Lewa Pole, Anja Rippert, Abdi Diriye, Pete Bull, Kevin Marsh, Steffen Borrmann, and Alexis Nzila
Reference: 
Antimicrob. Agents Chemother. 2009;53 5069-5073
Access: 
Restricted
Contact email: 
anzila@kilifi.kemri-wellcome.org

We have analyzed the in vitro chemosensitivity profiles of 115 Kenyan isolates for chloroquine (CQ), piperaquine, lumefantrine (LM), and dihydroartemisinin in association with polymorphisms in pfcrt at codon 76 and pfmdr1 at codon 86, as well as with variations of the copy number of pfmdr1.

_____________________________________________________________

In Vitro Activities of Piperaquine, Lumefantrine, and Dihydroartemisinin in Kenyan Plasmodium falciparum Isolates and Polymorphisms in pfcrt and pfmdr1.

Submitted by patrick sampao on November 18, 2009 - 12:47
Tags:
Author(s): 
Leah Mwai, Steven M. Kiara, Abdi Abdirahman, Lewa Pole, Anja Rippert, Abdi Diriye, Pete Bull, Kevin Marsh, Steffen Borrmann, and Alexis Nzila
Reference: 
Antimicrobial Agents and Chemotherapy, December 2009, p. 5069-5073, Vol. 53, No. 12, doi:10.1128/AAC.00638-09
Access: 
Restricted
Contact email: 
anzila@kilifi.kemri-wellcome.org

We have analyzed the in vitro chemosensitivity profiles of 115 Kenyan isolates for chloroquine (CQ), piperaquine, lumefantrine (LM), and dihydroartemisinin in association with polymorphisms in pfcrt at codon 76 and pfmdr1 at codon 86, as well as with variations of the copy number of pfmdr1.

_____________________________________________________________

Artemether Lumefantrine versus Dihydroartemisinin Piperaquine for Falciparum Malaria: A Longitudinal, Randomized Trial in Young Ugandan Children

Submitted by Inga on November 16, 2009 - 14:04
Tags:
Author(s): 
Emmanuel Arinaitwe, Taylor G. Sandison, Humphrey Wanzira, Abel Kakuru, Jaco Homsy, Julius Kalamya, Moses R. Kamya, Neil Vora, Bryan Greenhouse, Philip J. Rosenthal, Jordan Tappero, and Grant Dorsey
Reference: 
Clinical Infectious Diseases 2009; Volume 49, Number 11: Pages 1629–1637, DOI: 10.1086/647946
Access: 
Open access
Contact email: 
gdorsey@medsfgh.ucsf.edu

Artemisinin-based combination therapies are now widely recommended as first-line treatment for uncomplicated malaria. However, which therapies are optimal is a matter of debate. We aimed to compare the short- and longer-term efficacy of 2 leading therapies in a cohort of young Ugandan children.

_____________________________________________________________
Syndicate content